Login to Your Account

Inflarx on track with selective C5a antibody after positive phase IIa

By Cormac Sheridan
Staff Writer

Friday, January 29, 2016

DUBLIN – Inflarx GmbH hit the primary endpoint of a phase IIa trial of its first-in-class complement 5a-targeting antibody, IFX-1, in a trial of 72 intensive care unit (ICU) patients with early stage sepsis-associated organ dysfunction.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription